ASPEN: Randomised study to assess the effect of Brensocatib in patients with NCFBE

Posted by pfc202

The purpose of this study is to evaluate the efficacy, safety, and tolerability of brensocatib as treatment for NCFBE.

This is an experimental clinical research study of a study drug called brensocatib. “Experimental” means that the study drug is currently being tested in clinical research studies, and has not been approved for use in the treatment of patients with NCFBE. In addition, “experimental” means that we might not have all the information about brensocatib.

Before new drugs can be approved and sold to treat specific diseases, they must be tested in experimental clinical research studies. The results of such studies are then provided to the regulatory authorities. Brensocatib is not approved to treat NCFBE by the United States (US) Food and Drug Administration (FDA) or United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA), but it is undergoing clinical investigations to determine if brensocatib is safe and effective.

Click here for more information